Merck, a science and technology company, successfully completed the acquisition of the chromatography business of JSR Life Sciences. The move strengthens Merck’s capabilities in downstream processing and further expands its portfolio of solutions for biopharmaceutical manufacturing. By integrating advanced chromatography technologies, Merck aims to help pharmaceutical and biotechnology companies improve productivity, streamline purification processes, and accelerate the production of critical biologic medicines.
Expanding Downstream Processing Capabilities
The acquisition adds Amsphere™ Protein A resins and advanced Protein A chromatography technologies to Merck’s downstream processing portfolio. These technologies play a crucial role in the purification of monoclonal antibodies, one of the most important classes of biologic therapies used in modern medicine.
With these additional capabilities, Merck will enable customers to achieve more efficient and scalable purification processes. Moreover, when combined with Merck’s established downstream solutions, the new technologies will help improve process productivity and support reliable manufacturing from early development stages to full commercial production.
“This acquisition expands our downstream purification capabilities at a time when customers are pushing to scale biologics faster and more efficiently,” said Sebastián Arana, Head of Process Solutions, Life Science business of Merck.
He further noted that the expanded Protein A portfolio will allow Merck to help customers strengthen process consistency and ensure dependable manufacturing at scale. “With expanded Protein A offerings, we can help customers strengthen process consistency, support reliable manufacturing at scale, and ultimately accelerate access to critical therapies,” Arana added.
Strengthening Technical Expertise and Global Support
As part of the acquisition, Merck is also welcoming a Belgium-based chromatography team of more than 50 employees. This team has extensive expertise in chromatography technologies and currently provides solutions to pharmaceutical and biotechnology manufacturers worldwide. Their technical knowledge, application expertise, and customer support capabilities will further enhance Merck’s ability to assist customers in optimizing antibody purification processes.
Integration into Merck’s Process Solutions Portfolio
Going forward, the chromatography business will be integrated into Merck’s Process Solutions portfolio, a key segment within the company’s Life Science business. This portfolio supports biopharmaceutical manufacturers across the entire production cycle, including process development, scale-up, and commercial manufacturing. By combining JSR Life Sciences’ chromatography expertise with its own global infrastructure and technology platform, Merck aims to deliver more advanced and reliable solutions for the rapidly growing biologics market.
Supporting the Growing Demand for Biologic Therapies
The acquisition reflects Merck’s broader strategy to strengthen its position in the bioprocessing and biologics manufacturing sector, where demand continues to rise. As pharmaceutical companies accelerate the development of monoclonal antibodies and other biologic drugs, efficient purification technologies are becoming increasingly critical. As per the press release, with the addition of advanced Protein A chromatography technologies and specialized technical expertise, Merck is well positioned to help biopharmaceutical companies scale production efficiently while ensuring consistent quality and faster delivery of life-saving therapies to patients worldwide.
